About 盐酸卡博替尼 API

作用机制

Cabozantinib is a tyrosine kinase inhibitor that acts by blocking the activity of multiple tyrosine kinases, including MET and VEGFR2. Tyrosine kinases are enzymes that play a key role in signaling pathways that regulate cellular processes such as proliferation, migration, and angiogenesis.

In cancer, these signaling pathways are often dysregulated, leading to uncontrolled cell growth and survival. By inhibiting the activity of these kinases, cabozantinib can block these signaling pathways and potentially slow or stop the growth of cancer cells.

Specifically, cabozantinib has been shown to effectively inhibit the activity of MET, a tyrosine kinase that is overexpressed in many cancers and plays a key role in tumor growth, invasion, and angiogenesis. Inhibition of VEGFR2, another target of cabozantinib, can also block the growth of new blood vessels that tumors need to grow and spread.

Overall, the mechanism of action of cabozantinib involves blocking the activity of multiple tyrosine kinases involved in cancer cell growth and survival, ultimately leading to the inhibition of tumor growth.

适应症

Cabozantinib is an FDA-approved treatment for several types of cancer. It is indicated for the following indications:

Metastatic Renal Cell Carcinoma (mRCC): Cabozantinib is indicated for the treatment of patients with advanced or metastatic renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.

Medullary Thyroid Cancer (MTC): Cabozantinib is indicated for the treatment of patients with locally advanced or metastatic medullary thyroid cancer (MTC) who require systemic therapy and have received prior treatment with radioactive iodine.

Hormone-Relapsed Prostate Cancer: Cabozantinib is indicated for the treatment of patients with hormone-relapsed prostate cancer that has progressed during or after androgen deprivation therapy.

Advanced Liver Cancer: Cabozantinib is indicated for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib.

Dr. Reddy's的专长

Dr. Reddy's总部位于印度海得拉巴，是全球领先的活性药物成分（API）供应商之一。 Dr. Reddy's的API业务是美国、欧洲、巴西、拉丁美洲、日本、中国、韩国和新兴市场的制药公司的首选合作伙伴。

Dr. Reddy's博士的API业务在过去30多年来在开发和制造复杂API（如类固醇，多肽，复杂长链分子和高效API（HPAPI /肿瘤药物））方面所建立的深厚技术优势中茁壮成长。 我们在知识产权和法规事务方面的实力可以帮助我们始终如一地达到并超越监管标准，从而为这一专业知识提供补充。 Dr. Reddy's博士 盐酸卡博替尼 API是研发，知识产权和监管方面广泛专业知识的结果。

帮助我们的客户率先进入市场的关键组成部分是响应式供应链。 我们通过确保所有设施都高效运行并达到最新的质量，安全和生产率标准来实现这一目标。 业务和工厂之间的强大互联可以快速响应动态的市场变化，从而避免短缺并满足需求的突然激增。